AGARWALEYENSEDr. Agarwal's Health Care Limited· Healthcare ServicesHighNeutral
Announced Mon, 1 Jun, 2026 · 12:27 IST

NCLT Meeting Notice for AHCL-AEHL Amalgamation on July 2, 2026

Nclt Scheme FiledStrategic Transactions View source PDFExplain this filing

AGARWALEYE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.4%Reaction day
₹487.00
prior close
₹481.00
announcement price
In-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.1%-0.3% vs market
Hospital peers, median of 23sector-0.8%-0.6% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.3
10m
+0.3
15m
+0.2
30m
+0.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.4-1.1-0.3-0.8-0.6
Next day
-2.3-0.0-2.3-0.4-1.9
2d
-5.4+0.2-5.6+0.9-6.3
3d
-5.7+1.1-6.8+0.8-6.5
4d
-5.5+1.1-6.6+2.1-7.6
5d
-7.3-0.9-6.4+1.6-8.9
1w
-7.8-0.5-7.3+0.5-8.3
15d
-3.5+7.1-10.6+4.3-7.8
1m
-3.3+6.5-9.8+2.3-5.6
2m
-1.0+7.9-8.9+6.3-7.3
3m
+4.6+11.2-6.6+4.2+0.4
UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Notice of NCLT-ordered meeting of unsecured creditors of Dr Agarwal's Health Care on July 2, 2026 in Chennai to approve amalgamation of 72.67%-held subsidiary Dr Agarwal's Eye Hospital into the company. Remote e-voting June 7 to July 1, 2026. Scheme approved by Board August 2025; exchange no-objections received Feb 2026. Expected EPS accretive from year one.

Likely market impact

Creditors vote July 2 on AHCL-AEHL amalgamation. Key step toward merging listed subsidiary into parent; expected EPS accretive from year one.